Drug Profile
Semaglutide oral - Novo Nordisk
Alternative Names: GLP-1-SNAC; NN 6535; NN 9932; NN-9924; NNC0113-0217; OG-217SC; Rybelsus; SemagutideLatest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase III Alzheimer's disease; Obesity
Most Recent Events
- 26 Feb 2024 Novo Nordisk Withdrawn prior enrollment a phase III trial in Type 2 diabetes mellitus (Treatment-naïve, Newly diagnosed, In adults) in US, Brazil, Bulgaria, Croatia, Greece, Hungary, India, Malaysia, Mexico, Poland, Romania, Serbia, and Thailand due to internal reprioritization (NCT06083675)
- 16 Oct 2023 Novo Nordisk plans a phase III trial for Type 2 diabetes mellitus (Treatment-naïve, Newly diagnosed, In adults) in USA, Brazil, Bulgaria, Croatia, Greece, Hungary, India, Malaysia, Poland, Romania, Serbia, Thailand (PO) in January 2024 (NCT06083675)
- 02 Oct 2023 Efficacy data from the phase III SUSTAIN trial in Type 2 diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)